In high-grade serous ovarian cancer (HGSOC) (III and IV), dynamic analysis of ctDNA for BRCA1/2 reverse mutations or mutations in BRCA1 and TP53BP1 could predict response to PARP inhibitor therapy [30]. This evidence concerns the gene BRCA1 and ovarian serous adenocarcinoma.